(Q37462485)

20 August 2017

1 reference

title

The late adverse events of rituximab therapy--rare but there! (English)

1 reference

20 August 2017

1 reference

2

Isaac Ben-Bassat

1 reference

20 August 2017

3

Ofer Shpilberg

1 reference

20 August 2017

4

Aaron Polliack

1 reference

20 August 2017

Ron Ram

1

1 reference

20 August 2017

Pia Raanani

series ordinal

5

1 reference

20 August 2017

publication date

1 July 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

50

1 reference

20 August 2017

issue

7

1 reference

20 August 2017

page(s)

1083-1095

1 reference

The mechanisms of action of rituximab in the elimination of tumor cells

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

A new system for grading recommendations in evidence based guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Systematic review: agranulocytosis induced by nonchemotherapy drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Treatment of Waldenström's macroglobulinemia with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Proinflammatory syndrome mimicking acute rheumatoid arthritis in a patient with Waldenstrom's macroglobulinemia treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Tolerability and safety of rituximab (MabThera).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Successful high-titer immunoglobulin therapy for persistent parvovirus B19 infection in a lymphoma patient treated with rituximab-combined chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Fatal West Nile Virus infection after rituximab/fludarabine--induced remission for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Molecular evidence of persistent echovirus 13 meningoencephalitis in a patient with relapsed lymphoma after an outbreak of meningitis in 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Nadir B cell counts are significantly correlated with the risk of Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Risk factors for infection in haematology patients treated with rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma receiving chemotherapy containing rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Increased incidence of interstitial pneumonia by CHOP combined with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P carinii-specific antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Persistent and relapsing babesiosis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Monoclonal antibody therapy for B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

The human polyomavirus, JCV, uses serotonin receptors to infect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Molecular analysis of cerebrospinal fluid in viral diseases of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

The therapeutic potential of anti-CD20 "what do B-cells do?".

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Reactivation of hepatitis B virus with rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Safety of rituximab in lymphoma patients with hepatitis B or hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Presentation of HCV antigens to naive CD8+T cells: why the where, when, what and how are important for virus control and infection outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Concomitant treatment with lamivudine renders cladribine inactive by inhibition of its phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Rituximab-induced hepatitis C virus reactivation after spontaneous remission in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

B-cell depletion in the treatment of mixed cryoglobulinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and Overt B-cell malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Catastrophic gastrointestinal manifestations of post-transplant lymphoproliferative disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Fludarabine, cyclophosphamide and rituximab (FCR) induced pulmonary hypertension in Waldenstrom macroglobulinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Fatal interstitial pneumonitis related to rituximab-containing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Interstitial pneumonitis related to rituximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Rituximab-induced interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Enhancement of anti-lymphoma immuno-effects mediated by dendritic cells pulsed with heat-stressed and rituximab-coated CD20+ lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Tumor necrosis factor-alpha in a porcine bronchial model of obliterative bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

Initial immunoglobulin M ?flare? after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902934944

10.1080/10428190902934944

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference